Daqing Wu

2.2k total citations
56 papers, 1.7k citations indexed

About

Daqing Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Daqing Wu has authored 56 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 21 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Daqing Wu's work include Prostate Cancer Treatment and Research (20 papers), Bone health and treatments (7 papers) and Cancer, Lipids, and Metabolism (7 papers). Daqing Wu is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Bone health and treatments (7 papers) and Cancer, Lipids, and Metabolism (7 papers). Daqing Wu collaborates with scholars based in United States, China and Georgia. Daqing Wu's co-authors include Leland W.K. Chung, Haiyen E. Zhau, David M. Terrian, Wen‐Chin Huang, Fray F. Marshall, Shareen A. Iqbal, Shumin Zhang, Chia‐Ling Hsieh, Takeo Nomura and Majd Zayzafoon and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer Research.

In The Last Decade

Daqing Wu

54 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daqing Wu United States 24 942 460 329 279 167 56 1.7k
Suxia Han China 24 1.0k 1.1× 445 1.0× 299 0.9× 518 1.9× 159 1.0× 75 1.8k
Wenfeng Cao China 22 947 1.0× 396 0.9× 225 0.7× 456 1.6× 138 0.8× 59 1.6k
Shou‐Ching Tang United States 24 1.3k 1.3× 542 1.2× 230 0.7× 504 1.8× 175 1.0× 85 1.8k
Sven A. Lang Germany 24 928 1.0× 449 1.0× 174 0.5× 298 1.1× 218 1.3× 44 1.5k
Anica Dricu Romania 26 811 0.9× 374 0.8× 158 0.5× 423 1.5× 169 1.0× 78 1.6k
Renata Veselská Czechia 23 801 0.9× 505 1.1× 228 0.7× 282 1.0× 90 0.5× 72 1.5k
Lijun Di China 25 1.0k 1.1× 602 1.3× 188 0.6× 389 1.4× 236 1.4× 102 1.9k
Ken‐ichi Kozaki Japan 21 906 1.0× 312 0.7× 178 0.5× 357 1.3× 134 0.8× 34 1.5k
Yao Yuan China 20 855 0.9× 500 1.1× 185 0.6× 376 1.3× 174 1.0× 72 1.6k
JiHoon Kang South Korea 21 642 0.7× 493 1.1× 275 0.8× 476 1.7× 100 0.6× 63 1.4k

Countries citing papers authored by Daqing Wu

Since Specialization
Citations

This map shows the geographic impact of Daqing Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daqing Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daqing Wu more than expected).

Fields of papers citing papers by Daqing Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daqing Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daqing Wu. The network helps show where Daqing Wu may publish in the future.

Co-authorship network of co-authors of Daqing Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Daqing Wu. A scholar is included among the top collaborators of Daqing Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daqing Wu. Daqing Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bao, Qichao, Anil Kumar, Daqing Wu, & Jia Zhou. (2024). Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics. Drug Discovery Today. 29(6). 103986–103986. 6 indexed citations
2.
Bai, Lijuan, Xin Li, Yang Yang, et al.. (2023). Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Translational Oncology. 34. 101707–101707. 6 indexed citations
3.
Handy, Jeffrey A., et al.. (2023). Abstract C023: Aryl hydrocarbon receptor and leptin promote prostate cancer progression and may be associated with chemoresistance. Cancer Epidemiology Biomarkers & Prevention. 32(1_Supplement). C023–C023.
4.
Chen, Jianping, et al.. (2021). Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment. Current Topics in Medicinal Chemistry. 21(31). 2771–2777. 5 indexed citations
5.
Zhao, Rui, Xiaowei Ma, Lijuan Bai, et al.. (2021). Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. Neoplasia. 23(12). 1261–1274. 7 indexed citations
6.
Li, Xin, Lajos Gera, Shumin Zhang, et al.. (2021). Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 11(14). 6873–6890. 23 indexed citations
7.
Yang, Yang, Xin Li, Yanhua Chen, et al.. (2018). Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer. Molecular Cancer Therapeutics. 17(9). 1859–1870. 20 indexed citations
8.
Yu, Xiaolin, Sharad Ghamande, Haitao Liu, et al.. (2017). Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. Molecular Therapy — Nucleic Acids. 10. 317–330. 73 indexed citations
9.
Xiao, Hong, et al.. (2017). Effect of electroacupuncture on postoperative outcome in patients undergoing cardiac valve replacement with cardiopulmonary bypass. Zhonghua mazuixue zazhi. 37(1). 50–53. 2 indexed citations
10.
11.
Lu, Chunwan, et al.. (2016). Targeting translation: eIF4E as an emerging anticancer drug target. Expert Reviews in Molecular Medicine. 18. e2–e2. 44 indexed citations
12.
Liu, Hong Yan, Xiaolin Yu, Haitao Liu, Daqing Wu, & Jin‐Xiong She. (2016). Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer. Scientific Reports. 6(1). 30346–30346. 60 indexed citations
13.
Zhang, Shumin, Xu Wang, Shareen A. Iqbal, et al.. (2012). Epidermal Growth Factor Promotes Protein Degradation of Epithelial Protein Lost in Neoplasm (EPLIN), a Putative Metastasis Suppressor, during Epithelial-mesenchymal Transition. Journal of Biological Chemistry. 288(3). 1469–1479. 38 indexed citations
14.
Iqbal, Shareen A., Shumin Zhang, Adel Driss, et al.. (2012). PDGF Upregulates Mcl-1 Through Activation of β-Catenin and HIF-1α-Dependent Signaling in Human Prostate Cancer Cells. PLoS ONE. 7(1). e30764–e30764. 47 indexed citations
15.
Josson, Sajni, Takeo Nomura, Jen‐Tai Lin, et al.. (2011). β2-Microglobulin Induces Epithelial to Mesenchymal Transition and Confers Cancer Lethality and Bone Metastasis in Human Cancer Cells. Cancer Research. 71(7). 2600–2610. 104 indexed citations
16.
Zhang, Shumin, Haiyen E. Zhau, Adeboye O. Osunkoya, et al.. (2010). Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Molecular Cancer. 9(1). 9–9. 92 indexed citations
17.
He, Hui, Xiaojian Yang, Alec J. Davidson, et al.. (2009). Progressive epithelial to mesenchymal transitions in ARCaPE prostate cancer cells during xenograft tumor formation and metastasis. The Prostate. 70(5). 518–528. 31 indexed citations
18.
Wu, Daqing, H E Zhau, Wen‐Chin Huang, et al.. (2007). cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene. 26(35). 5070–5077. 112 indexed citations
19.
Wu, Daqing, Christopher W. Gregory, Douglas A. Weidner, et al.. (2003). Protein kinase Cɛ interacts with Bax and promotes survival of human prostate cancer cells. Oncogene. 22(39). 7958–7968. 91 indexed citations
20.
Wu, Daqing. (2002). Improving effect of carvedilol on ca rdiac function and exercise tolerance in patients with congestive heart fail-ure of dilated cardiomyopathy. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suxia Han Breakdown of academic impact, for papers by Wenfeng Cao Breakdown of academic impact, for papers by Shou‐Ching Tang Breakdown of academic impact, for papers by Sven A. Lang Breakdown of academic impact, for papers by Anica Dricu Breakdown of academic impact, for papers by Renata Veselská Breakdown of academic impact, for papers by Lijun Di Breakdown of academic impact, for papers by Ken‐ichi Kozaki Breakdown of academic impact, for papers by Yao Yuan Breakdown of academic impact, for papers by JiHoon Kang
Rankless by CCL
2026